Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taizishen Yue Capsule is a Traditional Chinese Medicine (TCM) candidate developed by Beijing Qingda Yinghua Biotechnology for the treatment of mild to moderate depression. The formulation is specifically designed to address the TCM patterns of qi-yin deficiency and heart-spleen deficiency. Its primary component, *Pseudostellaria heterophylla* (Taizishen or Prince Ginseng), is traditionally used to replenish qi and strengthen the spleen. The drug has undergone Phase 3 clinical testing in China (CTR20140128), where it was compared against the selective serotonin reuptake inhibitor (SSRI) fluoxetine and a placebo to evaluate its efficacy in reducing depressive symptoms and its safety profile in adult patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taizishen Yue Capsule.